| Literature DB >> 34851620 |
Dimitrios Karazisis1,2, Omar Omar3, Sarunas Petronis4, Peter Thomsen1, Lars Rasmusson1,2,5.
Abstract
Implant surface modification by nanopatterning is an interesting route for enhancing osseointegration in humans. Herein, the molecular response to an intentional, controlled nanotopography pattern superimposed on screw-shaped titanium implants is investigated in human bone. When clinical implants are installed, additional two mini-implants, one with a machined surface (M) and one with a machined surface superimposed with a hemispherical nanopattern (MN), are installed in the posterior maxilla. In the second-stage surgery, after 6-8 weeks, the mini-implants are retrieved by unscrewing, and the implant-adherent cells are subjected to gene expression analysis using quantitative polymerase chain reaction (qPCR). Compared to those adherent to the machined (M) implants, the cells adherent to the nanopatterned (MN) implants demonstrate significant upregulation (1.8- to 2-fold) of bone-related genes (RUNX2, ALP, and OC). No significant differences are observed in the expression of the analyzed inflammatory and remodeling genes. Correlation analysis reveals that older patient age is associated with increased expression of proinflammatory cytokines (TNF-α and MCP-1) on the machined implants and decreased expression of pro-osteogenic factor (BMP-2) on the nanopatterned implants. Controlled nanotopography, in the form of hemispherical 60 nm protrusions, promotes gene expressions related to early osteogenic differentiation and osteoblastic activity in implant-adherent cells in the human jaw bone.Entities:
Keywords: gene expression; human jaw; nanomedicine; nanotopography; osseointegration; osteogenic activities
Mesh:
Substances:
Year: 2021 PMID: 34851620 PMCID: PMC8672355 DOI: 10.1021/acsbiomaterials.1c00861
Source DB: PubMed Journal: ACS Biomater Sci Eng ISSN: 2373-9878
Demographic Data from the Patients Included in the Studya
| patient | age (years) | sex | medical background | medication | smoking | healing time (weeks) |
|---|---|---|---|---|---|---|
| 1 | 87 | male | 7 | |||
| 2 | 57 | female | ended 8 weeks prior to surgery | 8 | ||
| 3 | 43 | female | 6 | |||
| 4 | 63 | female | hypothyroidism | levaxin | 6 | |
| 5 | 42 | male | 8 | |||
| 6 | 56 | female | hypercholesterolemia | atorvastatin | 8 | |
| 7 | 68 | male | hypertension, hypercholesterolemia, myocardial infarction, hypothyroidism | trombyl, imdur, metoprolol, felodipin, losartan, simvastatin, levaxin | 8 | |
| 8 | 68 | female | hypertension, urinary incontinence | losartan, betmiga | 8 | |
| 9 | 64 | female | 8 | |||
| 10 | 69 | male | 8 |
Pregnant patients and patients with current smoking status, uncontrolled metabolic diseases, previous radiation therapy to the head and neck, or untreated oral diseases were excluded (n = 10).
List of Human Reference Genes Used in Screening for the Most Stable Reference Gene(s) for Normalization
| reference gene full name | abbreviation |
|---|---|
| 18S rRNA | RRN18S |
| β-actin | ACTB |
| β-2-microglobulin | B2M |
| β-glucuronidase | GUSB |
| glyceraldehyde-3-phosphate dehydrogenase | GAPDH |
| hypoxanthine phosphoribosyltransferase 1 | HPRT1 |
| peptidylpropyl isomerase
A | PPIA |
| 60S acidic ribosomal protein P0 | RPLP |
| TATAA-box binding protein | TBP |
| tubulin, β polypeptide | TUBB |
| tyrosine 3/tryptophan 5 -monooxygenase activation protein, ζ polypeptide | YWHAZ |
| ubiquitin C | UBC |
Peptidylpropyl isomerase A (PPIA) was selected as the best stable reference gene according to geNorm and NormFinder software.
Figure 1SEM evaluation: (A) Low-magnification overview of the mini-implant; (B) intermediate-magnification image of an implant with a machined surface; and (C) an implant with a nanopatterned surface. (D) High-magnification image of semispherical profiles on the nanopatterned surface. Images (B) and (C) were taken at the root of the implant thread. Image (D) was taken at the flank of the implant thread. All analyzed implants were sputter-coated with 30 nm titanium film and heat-treated.
Topographical Parameters of the Implants, as Analyzed by Optical Profilometry and SEM (n = 4)
| roughness measurements of the two implant types | M | MN | |
|---|---|---|---|
| microscale roughness parameters | mean roughness (Sa), nm | 296 ± 19 | 261 ± 32 |
| root-mean-square roughness (Sq), nm | 374 ± 20 | 325 ± 37 | |
| skewness | –0.01 ± 0.06 | 0.08 ± 0.12 | |
| kurtosis | 3.1 ± 0.2 | 3.1 ± 0.2 | |
| induced surface area, % | 10.7 ± 0.3 | 10.2 ± 2.0 | |
| nanoscale pattern parameters | semisphere diameter, nm | 51 ± 9 | |
| semisphere height, nm | 26 ± 4 | ||
| surface coverage, % | 8 ± 3 | ||
| distribution density, μm–2 | 40 ± 5 | ||
| center-to-center distance, nm | 130 ± 11 | ||
| induced surface area, % | 9 ± 3 | ||
Chemical Analysis of Implants by EDS (Atomic Concentration in %, n = 3)
| implant type | Ti (%) | O (%) | C (%) | Al (%) | Si (%) |
|---|---|---|---|---|---|
| before Ti-coating and heat treatment | 81.9 ± 0.4 | 12.3 ± 0.2 | 5.7 ± 0.2 | 0.13 ± 0.02 | 0.09 ± 0.03 |
| M | 55.7 ± 1.6 | 40.1 ± 1.6 | 4.1 ± 0.2 | 0.06 ± 0.01 | 0.03 ± 0.01 |
| MN | 53.9 ± 0.6 | 41.7 ± 0.7 | 4.3 ± 0.2 | 0.08 ± 0.01 | 0.04 ± 0.003 |
Figure 2Chemical analysis of implant surfaces using time-of-flight secondary ion mass spectrometry (TOF-SIMS, n = 3). The normalized intensities of the following ions were summed and are shown by the plotted bars: ∑C = CH3+, C2H5+, CH4N+, C3H5+, C3H7+, C4H7+, C6H5+, C7H7+, C9H7+, C14H30NO2+, C_2H–, CN–, C_16H_31O_2–, C_18H_35O_2–; ∑TiOx = ∧47TiO+, TiO+, TiO2H+, Ti2O3+, Ti2O4H+, Ti3O5+, Ti4O6+, Ti4O7+, Ti6O11+, TiO_2–, TiO_3–, TiO_3H–, Ti_2O_5H–, Ti_3O_7H–, ∑Metals = Na+, Al+, K+, Ca+, V+, Fe+, CaOH+, Ni+, Cu+, FeOH+, Pb+; ∑Si = SiO_2–, SiHO_3–, Si_2HO_5–, and Si_3HO_7–; ∑PS = positive ions with masses 103, 128, 152, 165, and 178 u; negative ions with masses 37, 49, 62, and 73 u; ∑Oxygen = O–, OH–.
Figure 3Boxplots showing the gene expression of inflammatory cytokines and chemokines in cells adherent to implants with a machined surface (M implants) and implants with a machined surface with superimposed nanotopography (MN implants) at retrieval after 6–8 weeks. (A) TNF-α, (B) IL-6, (C) MCP-1, and (D) IL-10. The data show the mean and standard error of the mean (n = 10). The boxplots show the median (line), mean (plus), first and third quartiles (box), minimum and maximum (whiskers), and all data values for the individual patients.
Figure 5Boxplots showing the expression of genes related to osteoclastic and osteoblast–osteoclast coupling activity in cells adherent to implants with a machined surface (M implants) and implants with a machined surface with superimposed nanotopography (MN implants) at retrieval after 6–8 weeks. (A) CTR, (B) CatK, (C) RANK, (D) RANKL, (E) OPG, and (F) RANKL/OPG ratio. The data show the mean and standard error of the mean (n = 10). The boxplots show the median (line), mean (plus), first and third quartiles (box), minimum and maximum (whiskers), and all data values.
Figure 4Boxplots showing the expression of genes related to osteogenic activity and osteoblastic differentiation in cells adherent to implants with a machined surface (M implants) and implants with a machined surface with superimposed nanotopography (MN implants) at retrieval after 6–8 weeks. (A) RUNX2, (B) ALP, (C) OC, and (D) BMP-2. The data show the mean and standard error of the mean (n = 10). Significant differences are indicated (p < 0.05). The boxplots show the median (line), mean (plus), first and third quartiles (box), minimum and maximum (whiskers), and all data values for the individual patients.
Correlation Analysisa
| M | MN | |||
|---|---|---|---|---|
| positive
correlations r ( | negative
correlations r ( | positive
correlations r ( | negative
correlations r ( | |
| older age | TNF-α 0.7 (0.02) | IL-10 0.7 (0.3) | BMP-2 -0.7 (0.03) | |
| MCP-1 0.8 (0.001) | ||||
| female sex | RUNX2 0.8 (0.002) | RANK -0.7 (0.02) | MCP-1 0.7 (0.02) | |
| OPG 0.8 (0.008) | ||||
| hypertension | MCP-1 0.7 (0.02) | |||
| angiotensin R blocker | MCP-1 0.7 (0.02) | |||
| hypercholesterolemia | IL-6 -0.7 (0.02) | |||
| several illnesses | IL-6 -0.7 (0.03) | |||
| statin drugs | IL-6 -0.7 (0.02) | |||
| several medications | IL-6 -0.7 (0.03) | |||
Data show positive and negative correlations between the patients’ demographic data/medical conditions and gene expression in cells adherent to implants with a machined surface (M) or implants with a machined surface and superimposed nanopattern (MN) (n = 10).